Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AML With FLT3 Mutation”

96 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 96 results

Large-scale testing (Phase 3)UnknownNCT04174612
What this trial is testing

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Gruppo Italiano Malattie EMatologiche dell'Adulto 172
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Not applicableStudy completedNCT04788420
What this trial is testing

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD MutationHematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 456
Testing effectiveness (Phase 2)Study completedNCT00079482
What this trial is testing

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Cephalon 224
Testing effectiveness (Phase 2)WithdrawnNCT02829840
What this trial is testing

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
LeukemiaFLT3-Mutated Acute Myeloid LeukemiaFLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Not applicableUnknownNCT05596968
What this trial is testing

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06667973
What this trial is testing

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaFLT3 Gene MutationAdult AML+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto 80
Testing effectiveness (Phase 2)Study completedNCT01522469
What this trial is testing

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc. 14
Large-scale testing (Phase 3)Not Yet RecruitingNCT07407140
What this trial is testing

VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 300
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 36
Large-scale testing (Phase 3)Active Not RecruitingNCT04027309
What this trial is testing

Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 777
Large-scale testing (Phase 3)UnknownNCT04716114
What this trial is testing

SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Who this might be right for
Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 315
Testing effectiveness (Phase 2)Study completedNCT02400281
What this trial is testing

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Who this might be right for
Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc. 28
Testing effectiveness (Phase 2)Looking for participantsNCT06696183
What this trial is testing

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Who this might be right for
AML - Acute Myeloid Leukemia
Technische Universität Dresden 60
Early research (Phase 1)Study completedNCT01578109
What this trial is testing

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Looking for participantsNCT04293562
What this trial is testing

Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
Children's Oncology Group 1,186
Testing effectiveness (Phase 2)Looking for participantsNCT06235801
What this trial is testing

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Study completedNCT03258931
What this trial is testing

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Who this might be right for
Newly Diagnosed FLT3 Mutated AML
Arog Pharmaceuticals, Inc. 214
Large-scale testing (Phase 3)Study completedNCT03250338
What this trial is testing

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc. 106
Load More Results